Literature DB >> 9453490

Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach.

G A Abrams1, N C Nanda, E V Dubovsky, M J Krowka, M B Fallon.   

Abstract

BACKGROUND & AIMS: We have reported that contrast echocardiography is a sensitive screening test for the hepatopulmonary syndrome (HPS). However, contrast echocardiography lacks specificity because many cirrhotic patients have positive study results with normal arterial blood gases and therefore do not fulfill criteria for HPS. The aim of this study was to assess the role of macroaggregated albumin lung perfusion scans (MAA scans) in the diagnosis of HPS.
METHODS: MAA scans were performed in 25 patients with HPS, 25 cirrhotic patients without HPS, and 15 hypoxemic subjects with intrinsic lung disease alone. An MAA shunt fraction was calculated from brain and lung counts.
RESULTS: MAA scan results were positive in 21 of 25 patients with HPS and negative in all controls. All 21 patients with positive MAA scans had PO2 values of <60 mm Hg. There was a strong inverse correlation between the degree of the MAA shunt fraction and arterial hypoxemia (r = -0.726).
CONCLUSIONS: A positive MAA scan result in cirrhosis is specific for the presence of moderate to severe HPS. We speculate that MAA scans may be particularly useful in evaluating the contribution of HPS to the hypoxemia in cirrhotic patients with intrinsic lung disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9453490     DOI: 10.1016/s0016-5085(98)70481-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  41 in total

1.  Hepatopulmonary syndromes.

Authors:  M J Krowka
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Hepatopulmonary syndrome.

Authors:  M B Fallon; G A Abrams
Journal:  Curr Gastroenterol Rep       Date:  2000-02

3.  The association of lipopolysaccharide and inflammatory factors with hepatopulmonary syndrome and their changes after orthotopic liver transplantation.

Authors:  Huimin Yi; Yuling An; Haijin Lv; Xuxia Wei; Xiaomeng Yi; Genshu Wang; Yang Yang; Guihua Chen; Shuhong Yi
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

4.  Pulmonary complications of cirrhosis.

Authors:  Rajan Kochar; Moises I Nevah Rubin; Michael B Fallon
Journal:  Curr Gastroenterol Rep       Date:  2011-02

Review 5.  Hepatopulmonary syndrome: What we know and what we would like to know.

Authors:  Israel Grilo-Bensusan; Juan Manuel Pascasio-Acevedo
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 6.  The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease.

Authors:  David S Goldberg; Michael B Fallon
Journal:  Clin Gastroenterol Hepatol       Date:  2015-04-28       Impact factor: 11.382

7.  Implications of estradiol and progesterone in pulmonary vasodilatation in cirrhotic patients.

Authors:  R Aller; J L Moya; S Avila; J Villa; V Moreira; R Bárcena; D Boxeida; D A de Luis
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

8.  High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systems.

Authors:  J H Henriksen; S Møller; S Schifter; J Abrahamsen; U Becker
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

9.  Development of hypoxemia in alcoholic liver disease.

Authors:  Shigeo Maruyama; Chisato Hirayama; Kazunori Maeda; Satoru Yamamoto; Masaharu Koda; Akihide Udagawa; Masayuki Inoue; Kensuke Umeki
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

10.  Pulse Oximetry Is Insensitive for Detection of Hepatopulmonary Syndrome in Patients Evaluated for Liver Transplantation.

Authors:  Kimberly A Forde; Michael B Fallon; Michael J Krowka; Michael Sprys; David S Goldberg; Karen L Krok; Mamta Patel; Grace Lin; Jae K Oh; Carl D Mottram; Paul D Scanlon; Steven M Kawut
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.